(Q79771416)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15018008%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

review article

1 reference

title

Cutaneous fungal infections in the elderly (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15018008%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

Daniel S Loo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15018008%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

publication date

1 January 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15018008%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15018008%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15018008%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15018008%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

33-50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15018008%20AND%20SRC:MED&resulttype=core&format=json

Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases

25 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

The diversity of Malassezia yeasts confirmed by rRNA sequence and nuclear DNA comparisons

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

The genus Malassezia with description of four new species

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Immunology of diseases associated with Malassezia species

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Clinically significant drug interactions in dermatology

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Reversible agranulocytosis associated with oral terbinafine for onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Reversible agranulocytosis associated with oral terbinafine in a pediatric patient

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Severe neutropenia associated with oral terbinafine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Drug interactions with itraconazole, fluconazole, and terbinafine and their management

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Drug interactions: Proteins, pumps, and P-450s

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Malassezia globosa as the causative agent of pityriasis versicolor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Oral therapy of common superficial fungal infections of the skin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Tinea pedis pathophysiology and treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Topical steroids versus systemic antifungals in the treatment of chronic paronychia: an open, randomized double-blind and double dummy study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Large-scale epidemiological study of the causal agents of onychomycosis: mycological findings from the Multicenter Onychomycosis Study of Terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

The diagnosis of nail fungus infection revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Office practice-based confirmation of onychomycosis: a US nationwide prospective survey

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Methods for diagnosing onychomycosis: a comparative study and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Dermatophytoma: Recalcitrance to treatment because of existence of fungal biofilm.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Long-term results in patients with onychomycosis treated with terbinafine or itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900109-8

7 January 2021

10.1016/S0733-8635(03)00109-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15018008%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference